11 Hemocyanins in the Immunotherapy of Superficial Bladder Cancer Sergio Arancibia1, Fabián Salazar1 and María Inés Becker1,2 1Fundación Ciencia y Tecnología para el…

Published OnlineFirst March 9, 2010; DOI: 10.1158/1078-0432.CCR-09-1961 Approaches to Phase 1 Clinical Trial Design Focused on Safety, Efficiency, and Selected Patient Populations:…

1. CXCR4 & SDF1 By : Najmaldin Saki 2008 2.   3.   4. chemokines (CXC , CC , C , CX3C) Chemokinesreceptors G protein-coupled receptor ( GPCR ) CXCR4 As a target in…

1. • recurrence rates of HCC after liver transplant are disappointing, (though improvement in outcomes are seen with better case selection) approx 5-year survival rates…

1. ACDS Laboratories A new biomarker for bladder cancer diagnosis Mirza Ahmed Katy Chun Sagar Desai Nik Sanyal August 29, 2013 2. Who We Are Dedicated to the advancement…

Slide 1The Science of Resveratrol Mark Lange, Ph. D. Market America Director of Quality Control Slide 2 Important Statement This presentation is on the latest research in…

Slide 1©2007 Myriad Genetic Laboratories, Inc. Slide 2 Learning Objectives At the conclusion of this presentation participants should understand the following: Use of pharmacogenetics…

Slide 1Tubulin Inhibition in Breast Cancer: A Therapeutic Target Critical to Improving Outcomes William J. Gradishar, MD Professor of Medicine Robert H. Lurie Comprehensive…

1. Please see full prescribing information. SUTENT® (sunitinib malate) Slide Kit . 2. Please see full prescribing information. 2 Contents Slide Indications 3 Dosing 4 Mechanism…

* * * Key Points Prostate cancer is the most common solid tumor affecting men, with an estimated 241,740 new cases in 20121 Estimates indicate that there are between 60,000…